News & Videos - THERAVET - English

Regulatory News: EGEIRO Pharma (ISIN Code: BE0974387194 - Mnemonic: ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, in particular for Idiopathic Pulmonary Fibrosis, announces that it has been informed of Euronext’s decision to classify the asset contribution of a license from H4 Orphan Pharma to TheraVet S.A. as a reverse takeover (RTO). This decision is based on two major factors: the contribution of a license valued at 14 million...

Regulatory News: EGEIRO Pharma (ISIN : BE0974387194 - mnemo : ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, notably in Idiopathic Pulmonary Fibrosis, announces that its Board of Directors meeting on November 15, 2024 has acknowledged the resignation of Enrico Bastianelli as a Director and has decided to modify its governance. Gaëtan Terrasse has been appointed Managing Director and Emmanuel Huynh Chairman. Catherine Bur remains a...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, provides the half-year update on its development strategy. Enrico Bastianelli, Chief Executive Officer of TheraVet , stated: “ The beginning of the year was rich in terms of market and product development. Supported by very good data, BIOCERA-VET ® COMBO-CLEAN, a new cement to be mixed with antibiotics, was...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, updates on the Osteosarcoma Program and on its participation at ESVONC (European Society of Veterinary Oncology) congress. With ~40,000 cases per year in Europe and the United-States, osteosarcoma is a high added value indication. Indeed, osteosarcoma is a severe disease with a poor prognosis severely impacting the quality of life of the patient due to severe...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the commercial launch of BIOCERA-VET ® Combo-Clean, a new reference for BIOCERA-VET, its comprehensive bone substitutes range, in Europe and United Kingdom. BIOCERA-VET ® Combo-Clean will be available on our website ( www.bioceravet.com ). Infections can be a major concern when it comes to orthopedic surgeries and can occur in 5% of these...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces its collaboration with Key Opinion Leaders in veterinary orthopedics for the assessment of BIOCERA-VET in complications of fracture associated with an impaired bone healing. As announced earlier this year, the Company continues to focus on enlarging the use of its BIOCERA-VET product line in new clinical indications. Impairment of the bone healing...

Regulatory News: TheraVet ( ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its Full-Year results for the year to December 31, 2022. The Company also informs its shareholders and the entire financial community of the availability of the preparatory documents for the ordinary general meeting of the Company to be held on June 1, 2023 at 5 p.m. (CEST) at 1070 Brussels, Allée de la...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the launch of its reference program dedicated to canine osteosarcoma. Each year in Europe and in the United States, ~40,000 dogs are diagnosed with bone cancer. When the diagnosis of osteosarcoma is made, the prognosis of these patients is generally poor and survival short. Pet owners then actively search for...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, provides an update on its development strategy. Enrico Bastianelli, Managing Director at TheraVet , states: “ Since the IPO of TheraVet in June 2021, we have been committed to deploying therapeutic innovations to treat osteoarticular pathologies in companion animals. Important milestones in this development were reached in 2022 with the...

Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET) (Brussels:ALVET) , a pioneering company in the management of osteoarticular diseases in pets , announces today the signing of an exclusive distribution agreement with Vetpharma, a leading company in the marketing of veterinary products. This agreement represents a significant step forward for the distribution of BIOCERA-VET ® product range, which is now available in the five continents. Thanks to this agreement with...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, is delighted to announce its collaboration with Dr Ter Braake, a European Specialist in Equine Surgery (Dierenkliniek Emmeloord, The Netherlands) in the evaluation of BIOCERA-VET ® Ready-To-Use as a new treatment option for horse bone cysts. Bone cysts are abnormalities of bones and joints that can occur in multiple sites in...

Regulatory News: TheraVet (ISIN code: BE0974387194 - mnemonic: ALVET), a pioneering biotechnology company in the treatment of bone and joint diseases in pets, today announces the signing of a new exclusive distribution agreement for its line of bone substitutes BIOCERA-VET ® with Elvetis, one of the main specialists in animal health products in France. The whole range, namely BIOCERA-VET ® Bone Surgery (BS) RTU, BIOCERA-VET ® BS Granules, BIOCERA-VET ® BS SmartGraft and BIOCERA-VET ®...

Regulatory News: TheraVet (ISIN code: BE0974387194 - mnemonic: ALVET), a pioneering biotechnology company in the treatment of bone and joint diseases in pets, today announces that BIOCERA-VET ® , its injectable bone cement, was nominated for the Veterinary Innovation Award (AFVAC, Marseille, France) and that, pursuing its commercial strategy, its management team participated in the following events: Veterinexpo 2022 November 26 & 27, 2022 (Liège) The largest veterinary fair in Wallonia,...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets , announces today it has entered into an exclusive distribution agreement with Invictos Orthopedics LLC, a North America company designing, developing and commercializing veterinary orthopedic products and medical devices. Harold Wotton, founder and Chief Executive Officer of Invictos Orthopedics, said: “The addition of the...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET), a pioneering company in the management of osteoarticular diseases in pets , announced today its participation in the annual congress of the European Society of Veterinary Orthopaedics and Traumatology (ESVOT) which will be held from 21 to 24 September at the Acropolis in Nice, France. With nearly 1000 participants, this event is the largest specialised congress in veterinary orthopaedics and traumatology in Europe,...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, today announces its financial results ended June 30, 2022 and provides an update on the development of its activities. The Company announces also the publication of its half-year financial report. Recent operational highlights Partnership agreement with Industrie Biomediche Insubri SA (IBI, Switzerland) broadening BIOCERA-VET ®...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering biotechnology company specialising in the management of osteoarticular diseases in pets, presents its half-year operational update ending June 30, 2022. Enrico Bastianelli, Chief Executive Officer of TheraVet, commented: “During this first half of the year, TheraVet achieved very important business milestones. Concerning BIOCERA-VET, in addition to the partnership agreement for...

Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets , announces today the commercial launch of its BIOCERA-VET ® products including BIOCERA-VET ® Bone Surgery Ready-to-Use, BIOCERA-VET ® Granules and BIOCERA-VET ® Osteosarcoma Ready-To-Use in United States of America. With about 89 million dogs, 104 million cats and a pet ownership above 50% 1 , it is the largest companion...

Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets , announces today the commercial launch of its new line of bone substitutes added over the past few months. BIOCERA-VET ® Bone Surgery Ready-to-Use, BIOCERA-VET ® Granules, BIOCERA-VET ® Smartgraft and BIOCERA-VET ® Osteosarcoma Ready-To-Use will be available for orthopedics surgeons in Belgium, France, Netherlands, United...

Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets , announces today the signing of an exclusive distribution agreement with Nuzoa, a leading Spanish company in the distribution of veterinary products and services. This agreement represents a significant step forward for the distribution of BIOCERA-VET ® product line in Spain, one of the five biggest European pet markets (with...